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BPH AND IPSS SCORES EVALUATED AFTER 6 MONTHS
ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
Marionneau N, Myon E, Charles T
Pierre Fabre, Boulogne-Billancourt, France
OBJECTIVES: Benign prostatic hyperplasia (BPH) occurs fre-
quently in middle-aged and elderly men. Recent epidemiologic
data suggest that 50% of men aged of 50 years are concerned.
Because of the growing elderly population in the industrialised
countries, the management of the disease is becoming a major
public health problem. A wide variety of medical treatment is
available, and the ﬁnancial burden associated to it is increasing.
This is a public health problem with a number of diagnostic,
therapeutic and economic facets. The severity of the problem is
assessed by the score obtained on the IPSS, a well known and
recognised questionnaire. METHODS: More than 700 patients
with BPH diagnosed for less than 3 months will be included in
the CHOQ program by 250 general practitioners. Every 6-
months, and for at least 3-years, the patient and his partner will
ﬁll out a quality of life questionnaire. This questionnaire is com-
posed of a generic instrument that assesses the general health
condition, and 5 speciﬁc instruments that investigate the conse-
quences of the BPH on sexuality, sleeping and urinary symptoms.
RESULTS: Using a follow-up cohort study, we isolated two
groups presenting a recently diagnosed BPH: the ﬁrst patient
population was kept under watchful waiting (n = 101) versus a
second patient population undergoing treatment with Serenoa
repens (n = 112). For the patients under watchful waiting, the
IPSS score was respectively 11.8 (5.7) and 10.9 (6.7) upon
patient inclusion and after 6 months. This difference is not sta-
tistically signiﬁcant. However, for the patients treated with
Serenoa repens, the IPSS score was respectively 14.3 (6.6) and
11.9 (5.7) upon patient inclusion and after 6 months. The noted
difference is statistically signiﬁcant (p < 0.0001). CONCLU-
SIONS: Patients suffering from a recently diagnosed BPH and
treated with Serenoa repens thus showed a statistically signiﬁ-
cant improvement as demonstrated by the IPSS score.
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BENIGN PROSTATIC HYPERPLASIA: CROSS EVALUATION OF
THE GP-PATIENT IPSS
Perrin P1, Marionneau N2, Rufﬁon A1, Myon E2,Taïeb C2
1Lyon Sud Hospital, Pierre Bénite, France; 2Pierre Fabre, Boulogne-
Billancourt, France
OBJECTIVES: To compare the results obtained with the IPSS
administered by GP (GP-IPSS) versus a self administered ques-
tionnaire (patient-IPSS). METHODS: A total of 338 recently
diagnosed BPH patients were involved in the analyses. For each
of them, their GP (General Practionner) ﬁlled an GP-IPSS ques-
tionnaire in according to their knowledge of their patients. The
patient completed the patient-IPSS questionnaire himself and
send it back to data management center through a prepaid enve-
lope to avoid patient’s answers to be viewed by the GP. Bland &
Altman method was chosen to visualize individual difference and
to quantify the bias. RESULTS: On average GP overestimated
by 1.3 points [0.9–1.7] 95% the IPSS compared to patient self
evaluation. Individual discrepancies reached 3 points or more
among 42% of patients. The results of GP-IPSS were signiﬁcantly
higher at 6 months, 12 months and 18 months taking into
account Bonferoni correction. CONCLUSIONS: There was a
statistically signiﬁcant bias between GP’s administered IPSS and
self administered IPSS. We recommend to always keeping the
same IPSS administration’s mode during the course of a clinical
trial.
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ESTIMATION AND ANALYSIS OF DIRECT MEDICAL COST OF
SECONDARY HYPERPARATHYROIDISM (SHPT) IN DIALYSIS
PATIENTS
Rosillon D1, Ducarme X1, Lins RL2, Standaert B3
1SGS Biopharma, Wavre, Belgium; 2ZNA Stuivenberg, Antwerp,
Belgium; 3Amgen n.v, Brussels, Belgium
Secondary hyperparathyroidism (SHPT) is frequently observed
in dialysis patients leading to costly to treat health complications.
OBJECTIVES: To assess whether direct medical costs signiﬁ-
cantly vary with SHPT conditions. METHODS: Direct medical
cost and resource use data were retrospectively collected from
patient medical ﬁles and invoices of 75 dialysis patients over
maximum period of 2 years prior to death in 3 dialysis centres
in Belgium. Total collection period was segmented into two
SHPT condition episodes deﬁned by PTH values £ or >300pg/
mL, using linear interpolation lines between subsequent PTH
measurements. Costs were retrieved from hospital invoices,
including start and stop date of each bill and cost category (hos-
pitalisations, medications, dialysis, laboratory tests, honoraria,
and other). To overcome problems of incomplete invoices, an
invoice coverage factor was developed comparing available
invoices with health care resource utilisation from medical ﬁles.
Periods with insufﬁcient coverage were discarded. Resource use
and costs were attributed to each individual PTH condition
episode. Statistical modeling: Because of heavily skewed cost
data, incomplete data sets, the need to adjust cost results for time
to death and centre effect, mixed models on non-transformed
and log-transformed costs and General Linear Model (GLM)
with a gamma response probability distribution and a loglink
function were used. RESULTS: Results expressed as mean cost
per day show that periods with elevated PTH-values lead to
higher costs compared to normal periods (average cost-difference
per day: approximately €50; p < 0.05). Results will further be
discussed regarding distribution of residuals, and hypothesis
testing. To assess robustness of results, three sensitivity analyses
were performed: analysis on subjects having experienced both
PTH conditions before death; analysis over different observation
periods using 6 months incremental time periods; cost deprecia-
tion factor. CONCLUSIONS: The statistical method allowed
obtaining robust and valuable cost estimates for different SHPT
conditions.
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EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY
WITHIN AN OVERACTIVE BLADDER POPULATION
Bridge S1, Solanki J1, Lister S2








OBJECTIVE: Overactive Bladder (OAB) syndrome is deﬁned
symptomatically and is suggestive of detrusor overactivity.
Detrusor overactivity can occur due to an underlying neurolog-
ical disease (neurogenic detrusor overactivity). Early identiﬁca-
tion of neurogenic detrusor overactivity may facilitate more
effective management. The objective of our study was to explore
the likely indicators supporting a neurogenic cause for detrusor
overactivity within an OAB population, providing a clearer case
for proactive investigation of bladder problems. METHODS:
The DIN–LINK database was used to conduct a 1–year retro-
spective cohort analysis of patients across Great Britain with
OAB and neurological disease. Patients who had an OAB
symptom(s) and/or a prescription for an OAB–related therapy
during the study period (September 2003–August 2004) were
included in this analysis and constituted the OAB cohort. All the
records of those within the cohort were analysed to identify
whether the patient was diagnosed or receiving treatment for
Parkinson’s disease, stroke, multiple sclerosis or spinal cord
injury. Data was analysed by age, gender and OAB symptoms.
RESULTS: The cohort contained 13,482 OAB patients, repre-
senting a prevalence of 1.7% of the population (n = 815,054) of
whom 61% (n = 8150) were women and 43% were aged over
65. In total, 1314 (10%) patients had a neurological disease, this
increased to 16% (948 patients) in those over 65. Incontinence
was experienced by 29% (n = 384) of those with a neurological
disease but in only 18% of the complete cohort. Those with neu-
rological disease also more commonly experienced urinary fre-
quency. CONCLUSION: This study suggests that there is value
in assessing patients who present with OAB symptoms for early
signs of underlying neurological conditions. It is important to
identify neurological disease as the cause of detrusor overactiv-
ity. This will help clinicians understand the aetiological factors
behind the condition and also help in its overall management.
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BENIGN PROSTATE HYPERPLASIA: MUST BOTHERSOMENESS
OF SYMPTOMS BE PRIVILEGED?
Perrin P1, Marionneau N2, Cucherat M3,Taïeb C2, Myon E2
1Lyon Sud Hospital, Pierre Bénite, France; 2Pierre Fabre, Boulogne-
Billancourt, France; 3University Teaching Hospital (CHU), Pierre
Bénite, France
OBJECTIVES: The IPSS evaluates the frequency of lower urinary
tract symptoms (LUTS). The SPI score (Symptom Problem Index)
evaluates the degree of discomfort associated with each question
on the IPSS. Our objective was to clarify the possibility of a sub-
stitution of the IPSS and SPI rating scales. METHODS: The IPSS
and SPI questionnaires were self-administered to a cohort of 907
male patients presenting a BPH recently diagnosed. The rela-
tionship between SPI and IPSS was investigated through the cor-
relation between the 2 scores and by the classiﬁcation of each
symptom according to its frequency on the one hand, and the
bothersomeness that it induces on the other. RESULTS: The
mean IPSS score was 12.6 +/- 6.4, the mean SPI score was 12.2
+/- 6.5.The correlation coefﬁcient between the IPSS and SPI
scores was 0.70; the scores from the 2 rating scales showed a
very high variability. On a 0–100% scale, where 100% repre-
sents the maximal possibility, the degree of bothersomeness
observed in the cohort ranged from 35 to 55%, the induced
bothersomeness ranged from 0 to 22.6% and the frequency of
the symptoms observed ranged from 26 to 44% depending on
the 7 symptoms. CONCLUSIONS: The two questionnaires do
not collect the same information. Considering the importance of
bothersomeness associated with lower urinary tract symptoms
for making the decision about therapy, the joint use of the IPSS
and SPI seems appropriate.
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INDUCED BOTHERSOMENESS IN THE ANALYSIS OF THE IPSS
QUESTIONNAIRE
Marionneau N1, Perrin P2, Charles T1, Myon E1, Cucherat M3
1Pierre Fabre, Boulogne-Billancourt, France; 2Lyon Sud Hospital, Pierre
Bénite, France; 3University Teaching Hospital (CHU), Pierre Bénite,
France
OBJECTIVES: The International Prostatic Symptom Score
(IPSS) evaluates urinary disorders symptoms frequency associ-
ated with benign prostatic hyperplasia, but does not take into
account the bothersomeness that they induce. The Symptom
Problem Index (SPI) evaluates the degree of discomfort associ-
ated with each question on the IPSS. Our objective is to quan-
tify the degree of bothersomeness induced by each BPH
symptom. METHODS: A cohort of 907 male patients with BPH
was monitored by French General Practitioners (GP). The IPSS
and SPI questionnaires were self-administered. The IPSS and SPI
scores were evaluable for 722 patients. The relationship between
SPI and IPSS was investigated through the correlation between
the 2 scores and by the construction of quadratic curve estima-
tions for each symptom. The degree of bothersomeness that each
symptom induces was explored by the Area Under the Curve
(AUC) corresponding to an IPSS item score equal to or greater
than 2 points. RESULTS: The mean IPSS score was 12.6 +/- 6.4,
the mean SPI score was 12.2 +/- 6.5. The correlation coefﬁcient
between the IPSS and SPI scores was 0.70; the scores from the
2 rating scales showed a very high variability. Induced bother-
someness varied from 0 to 23% according to the symptom eval-
uated. Nocturia seems to be the most important symptom taking
into account the bothersomeness it caused. Despite weak urinary
stream was the most frequent symptom in this cohort, it was
only involved in 4% of induced bothersomeness. CONCLU-
SIONS: The two questionnaires do not collect the same infor-
mation. The concept of induced bothersomeness allows a more
reﬁned analysis of the extent of bothersomeness associated with
each question on the IPSS. If we accept the hypothesis that both-
ersomeness is the main parameter that leads to a treatment deci-
sion, the joint use of the IPSS and SPI seems appropriate.
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PATIENT SATISFACTION: INTERNATIONAL DEVELOPMENT,
TRANSLATABILITY ASSESSMENT AND LINGUISTIC
VALIDATION OF THE OAB-S,AN OVERACTIVE BLADDER
TREATMENT SATISFACTION QUESTIONNAIRE
Conway K1, Piault EC2, Kopp Z3,Abrams P4, Brubaker L5
1Mapi Research Institute, Lyon, France; 2Mapi Values, Boston, MA,
USA; 3Pﬁzer Inc, New York, NY, USA; 4Bristol Urological Institute,
Bristol, UK; 5Loyola University Medical Center, Maywood, IL, USA
OBJECTIVE: The Overactive Bladder Treatment Satisfaction
Questionnaire (OAB-S) is a self-administered instrument assess-
ing treatment satisfaction in patients with overactive bladder.
The OAB-S has been developed for worldwide use; moreover, its
conceptual equivalence and cultural adaptability across countries
were considered early in the development process. To date, the
OAB-S is available in ﬁve languages including US-English, US-
Spanish, UK-English, Spain-Spanish and German. METHODS:
The cultural and linguistic equivalence of the OAB-S was ensured
at different stages of the development and the translation
processes: 1) the OAB-S was simultaneously developed in US-
English and US-Spanish and tested for face and content validity;
2) the pre-ﬁnal original questionnaire underwent a translatabil-
ity assessment, an international critical review with the objective
of suggesting re-formulations in the pre-ﬁnal version considering
the context and constraints of other languages and cultures; 3)
ﬁnally, the OAB-S was translated into the three remaining lan-
